Billy Goat Brands

Billy Goat Brands Joins SeaLegacy's Good Ocean Supporting Critical Ocean Conservation Work

  • The Company's Commitment is Aligned with its Focus on the Oceans and Proactive Attentiveness to the Growing Consumer Demand for Accountability in how Products are Made, Sold and Marketed
  • SeaLegacy a Global Non-Profit Using the Power of Media and Storytelling to Amplify Ocean Solutions
  • Funds Raised Through SeaLegacy's Good Ocean Support Impact Grants to Organizations Leading On-the-Ground Projects that Conserve Oceans While Building a More Just and Equitable Planet
  • SeaLegacy and its Co-Founders Boast a Combined Audience of Over 10 Million Instagram Followers

Billy Goat Brands Ltd. ("GOAT" or the "Company") (CSE: GOAT) (OTCQB: BGTTF) (FRA: 26B), a venture capital platform focused on identifying, sponsoring and incubating high-potential companies in the ocean economy, is pleased to announce a one-year commitment to SeaLegacy (" SeaLegacy ") through The Good Ocean (" Good Ocean " or the " Program "). SeaLegacy is an organization that uses a variety of collaborations, experts and the latest digital and social technologies to aid in the building of a healthy future for oceans across the world. The Good Ocean is a community of businesses that supports SeaLegacy's mission and aligns with its values to create a better planet. GOAT is dedicated to making a difference when it comes to the sustainability of oceans through sustainable commerce, which is reinforced by its sponsorship of the Program.

The Company will be acknowledged on SeaLegacy's established social media network and website, be exposed to exclusive networking opportunities, have access to visual assets provided by SeaLegacy and the Program, as well as work with the communications team to create other bespoke amplification opportunities. SeaLegacy has a wide reach with 2.4 million followers on its @sealegacy Instagram account, while its Co-Founders Cristina Mittermeier and Paul Nicklen have 1.5 million and 7.3 million followers on their @mitty and @paulnicklen Instagram accounts, respectively. Therefore, the SeaLegacy team is creating ocean conservation awareness on an unmatched scale.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/42670a42-d7f5-468c-8c4d-5d301657415c

Members of The Good Ocean share a common love of the ocean and are eager to help reverse the destruction that is currently occurring. More than 70% of the planet is covered in water, and yet less than 2% of the ocean is fully protected. 1 The Program is unified, passionate, and takes a business approach to increase the protection of the world's oceans. GOAT, as a new member of The Good Ocean, is committing to supporting the development of a more sustainable ocean economy through its operations and investments. SeaLegacy aligns with businesses who genuinely care about their impact on the ocean – and the planet – and are proactively attentive to the growing consumer demand for accountability in how products are made, sold and marketed.

Additionally, The Good Ocean has recently announced a partnership with the Professional Association of Diving Instructors (PADI) to accelerate the protection of 30% of the ocean by 2030 and is participating in a campaign to protect the New Zealand shark community from poaching. More information on The Good Ocean can be found on its website: https://www.sealegacy.org/pages/good-ocean .

Management Commentary

"SeaLegacy's Good Ocean is a community of passionate and proactive businesses unified by an ability and commitment to disrupt their industry," said Cristina Mittermeier, Co-founder and President of SeaLegacy. "Our members are leaders in their space, responding to the growing consumer demand for accountability in how products are produced, distributed and packaged. I am honored that the team at GOAT has chosen to align with SeaLegacy, and together, we can take steps towards systemic change in our consumer culture," added Ms. Mittermeier.

"GOAT is a proud new member of SeaLegacy's Program, which is a growing community of aligned businesses guided by a commitment to respond quickly to the urgent need to make systemic changes in consumer habits regarding our oceans. We are excited to participate in making sustainable choices and encouraging other businesses to do the same, while encouraging strong returns on investment and high levels of customer satisfaction," said Tony Harris, Chairman and Chief Executive Officer of GOAT.

ABOUT SEALEGACY

SeaLegacy, in partnership with action hub Only One, is building a global movement of ocean activists who support critical ocean conservation and climate solutions — to drive meaningful change for our planet in this decade. Founded by Cristina Mittermeier, Paul Nicklen and Shawn Heinrichs, SeaLegacy leverages compelling visual storytelling content to move people from apathy to action, countering climate anxiety by connecting people everywhere with opportunities to catalyze change, fund innovative solutions, and drive significant impact for the ocean and our planet. More information about SeaLegacy can be found on its website: https://www.sealegacy.org .

ABOUT BILLY GOAT BRANDS

Billy Goat Brands is a venture capital platform focused on identifying, sponsoring and incubating high-potential companies in the ocean economy. It intends to accomplish these goals through the identification of and investment in the securities of private businesses that are involved in the food and beverage industry, with a focus on: (i) plant-based protein, (ii) functional foods, (iii) food technology, and (iv) sustainable packaging technologies. The Company plans to generate returns on its investments through various outcomes, including but not limited to go-public transactions, mergers or acquisitions, and the other liquidity events of its investee companies or projects. The paramount goal of Billy Goat Brands will be to generate maximum returns from its investments in a manner consistent with its environmental, social and governance values.

For more information about the Company, please visit https://billygoatbrands.com/ . Its final prospectus, financial statements and management's discussion and analysis, among other documents, are all available on the Company's profile page on SEDAR at www.sedar.com .

The CSE has neither approved nor disapproved the contents of this news release. Neither the CSE nor its Market Regulator (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

On behalf of:

Billy Goat Brands Ltd.

"Tony Harris"

Tony Harris, CEO & Chairman
Tel: (778) 222-8221

For further information, please contact:

Investor Relations
Email: info@billygoatbrands.com
Tel: 1-833-4-GOAT-IR (1-833-446-2847)

CAUTIONARY STATEMENT REGARDING "FORWARD-LOOKING" INFORMATION

This news release contains certain forward-looking statements within the meaning of such statements under applicable securities law. Forward-looking statements are frequently characterized by words such as "anticipates", "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed", "positioned" and other similar words, or statements that certain events or conditions "may" or "will" occur. The Company has provided the forward-looking statements in reliance on assumptions that it believes are reasonable at this time. All such forward-looking statements involve substantial known and unknown risks and uncertainties (including those risk factors identified in the Company's prospectus dated September 8, 2021), certain of which are beyond the Company's control. Such risks and uncertainties include, without limitation, delays resulting from or inability to obtain required regulatory approval. The reader is cautioned that the assumptions used in the preparation of the forward-looking statements may prove to be incorrect and the actual results, performance or achievements could differ materially from those expressed in, or implied by, these forward-looking statements. Accordingly, no assurances can be given that any of the events anticipated by the forward-looking statements will transpire or occur, or if any of them do, what benefits, including the amount of proceeds, the Company will derive therefrom. Readers are cautioned that the foregoing list of factors is not exhaustive. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether because of new information, future events or otherwise, except as expressly required by applicable law.

Endnotes

  1. "Urge world leaders to protect 30% of the ocean by 2030", Only One Inc., 2022, https://only.one/act/ocean30

SOURCE: Billy Goat Brands Ltd.


Primary Logo

News Provided by GlobeNewswire via QuoteMedia

GOAT:CC
The Conversation (0)
GOAT Enters Into Letter of Intent to Acquire Canadian License for Direct Lithium Extraction Technology

GOAT Enters Into Letter of Intent to Acquire Canadian License for Direct Lithium Extraction Technology

GOAT Industries Ltd. (the " Company " or " GOAT ") (CSE: GOAT), is pleased to announce the Company has entered into a non-binding Letter of Intent (the " LOI ") dated September 14, 2022 with 1000288601 Ontario Inc. (" Ontario Co ").

The LOI contemplates a proposed transaction (the " Proposed Transaction "), whereby GOAT would acquire all issued and outstanding securities of Ontario Co by way of a share exchange agreement (the " Share Exchange "). Ontario Co is in the process of acquiring the Canadian license for a Direct Lithium Extraction technology (the " DLE Technology ") developed by private industry, as well as University researchers based out of Australia.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
GOAT Announces Corporate Rebrand

GOAT Announces Corporate Rebrand

GOAT Industries Ltd. (the " Company " or " GOAT ") (CSE: GOAT), is pleased to report that in conjunction with its name change to GOAT Industries Ltd., the Company has launched its rebranded corporate website and investor presentation which can be viewed at: https:www.goatindustries.co .

GOAT's Management encourages all shareholders to visit the website and explore its redesign initiatives.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Billy Goat Provides H2 Guidance for FunGuys Beverages

Billy Goat Provides H2 Guidance for FunGuys Beverages

Billy Goat Brands Ltd. (the " Company " or " GOAT ") (CSE: GOAT), is pleased to report that FunGuys Beverages (" FunGuys "), a 100-per-cent wholly owned subsidiary of GOAT has successfully achieved Phase II certification of TerraCycle's LOOP (" LOOP ") testing protocols. This operational milestone further demonstrates FunGuys's market position as a socially responsible distributor of organic mushroom-infused cold brew coffee beverages underpinned by proprietary formulation stack.

FunGuys's commercial associations with LOOP enables it to leverage reusable packaging for its line of Kold-branded beverages. As previously announced, LOOP's stringent design guidelines will enable Kold products to move from single-use packaging to a multiuse ecosystem while also providing FunGuys with access to a scalable sales channel through LOOP 's integrated network of retail partners. Recently, LOOP was invited to present its views on sustainable business practices at the World Economic Forum and has support from major North American and European grocers, retailers and packaged good brands.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Billy Goat Brands Announces Name Change

Billy Goat Brands Announces Name Change

Billy Goat Brands Ltd. (the " Company " or " GOAT ") (CSE: GOAT), is pleased to announce that, subject to the approval of the Canadian Securities Exchange (" CSE "), effective September 12, 2022, the Company intends to change its name to "GOAT Industries Ltd." from "Billy Goat Brands Ltd." (the " Name Change ") The Company will continue to trade under the stock symbol "GOAT" on the CSE, under the stock symbol "BGTTF" on the OTCQB Venture Market and under the symbol "26B" on the Frankfurt Stock Exchange.

No action is required to be taken by shareholders with respect to the name change. Outstanding share certificates are not affected by the name change and do not need to be exchanged. The Company's ISIN and CUSIP numbers for the common shares will change to CA3802J1030 and 38021J103, respectively.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Billy Goat Acquires Kojo Pet Performance

Billy Goat Acquires Kojo Pet Performance

Billy Goat Brands Ltd. (the " Company " or " Billy Goat ") (CSE: GOAT), is pleased to announce that further to its news release dated June 30, 2022, it has completed the acquisition of Kojo Pet Performance Inc. (" Kojo ") in consideration of 25,000,000 common shares of the Company (each a " Consideration Share ") issued at a deemed price of $0.039 per share to the existing shareholders of Kojo (collectively, the " Vendors "). Kojo is an innovative pet-food brand focused on producing and marketing plant and cell-based pet food offerings.

Furthermore, the Vendors are eligible to earn up to an additional 30,000,000 Consideration Shares upon the realization of the following performance milestones by Kojo within 36 months from the date of closing:

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
AbbVie Features New Data Across Difficult-to-Treat Solid Tumors and Blood Cancers at ASCO 2025, Highlighting Breadth and Depth of its Oncology Portfolio

AbbVie Features New Data Across Difficult-to-Treat Solid Tumors and Blood Cancers at ASCO 2025, Highlighting Breadth and Depth of its Oncology Portfolio

- Key oral presentations highlight new data from AbbVie's novel investigational antibody-drug conjugates (ADCs) including telisotuzumab adizutecan (ABBV-400, Temab-A) in advanced non-small cell lung cancer (NSCLC), ABBV-706 in high-grade neuroendocrine neoplasms (NENs) and pivekimab sunirine (PVEK) in blastic plasmacytoid dendritic cell neoplasm (BPDCN).

AbbVie (NYSE: ABBV) today announced that key data from its broad oncology portfolio will be showcased across multiple oral presentations and posters at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting ( May 30 - June 3, 2025 ). These new data highlight significant progress in AbbVie's robust oncology pipeline, across a range of difficult-to-treat solid tumors and blood cancers.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
AbbVie and U of T Mississauga's SpinUp Announce Neuropeutics Inc as First AbbVie Biotech Innovators Award Recipient

AbbVie and U of T Mississauga's SpinUp Announce Neuropeutics Inc as First AbbVie Biotech Innovators Award Recipient

  • Following a national competition, AbbVie and SpinUp – the University of Toronto's lab-based, life sciences accelerator – announce Neuropeutics Inc as recipient of first AbbVie Biotech Innovators Award
  • Neuropeutics Inc receives a year of laboratory space and equipment at no cost, as well as access to support and mentorship

AbbVie (NYSE: ABBV) in partnership with the University of Toronto's SpinUp, are pleased to announce Neuropeutics Inc as the recipient of the AbbVie Biotech Innovators Award, a national prize to help foster innovation and support growth in Canada's life sciences sector. Following a competitive selection process, the award, funded by AbbVie, has been granted to Neuropeutics Inc for developing small molecules preventing and reversing protein aggregation as therapeutics for neurodegenerative diseases.

AbbVie Biotech Innovators Award. (CNW Group/AbbVie Canada)

"We are delighted to have this opportunity to collaborate with a global biopharmaceutical company such as AbbVie, and the University of Toronto's SpinUp, to advance Neuropeutics' therapeutic research and development across multiple neurodegenerative diseases. At Neuropeutics, we are committed to developing targeted therapies to extend neurodegenerative disease patients' survival and improve their quality of life. This award allows us to pursue that mission with greater momentum," said Dr. Marc Shenouda , CEO & Co-Founder of Neuropeutics Inc.

Neuropeutics Inc's scientific entrepreneurial spirit directly aligns with the mandate of the AbbVie Biotech Innovators Award to foster research, innovation and growth within Canada's life sciences sector. A hallmark of neurodegenerative diseases is protein aggregation. One such protein is TDP-43, a normally nuclear DNA/RNA binding protein, which in disease conditions becomes mislocalized and forms cytoplasmic aggregates causing neuronal toxicity. Neuropeutics Inc has developed a novel strategy to address diseases such as: Amyotrophic Lateral Sclerosis (ALS), Frontotemporal dementia, Alzheimer's disease, Huntington's disease and Parkinson's disease.

"It was impressive and motivating to see the variety of entries and the calibre of early-stage biotech companies who applied for the Award. We thank all who participated in this life science competition," said Rami Fayed, Vice President and General Manager of AbbVie Canada. "After a rigorous evaluation process, it is with great pleasure that we are announcing that Neuropeutics has been named the recipient of the AbbVie Biotech Innovators Award for its pioneering work in neurodegenerative diseases. We look forward to supporting the journey of Neuropeutics, in collaboration with SpinUp, to accelerate their efforts to deliver life-changing innovation to patients."

"Congratulations to Neuropeutics on being the first AbbVie Biotech Innovators Award recipient, and welcome to SpinUp – the University of Toronto's wet lab incubator," said France Gagnon , Vice-Principal, Research and Innovation at the University of Toronto Mississauga. "This is the place where the potential of Neuropeutics' work in neurodegenerative diseases can be realized and the impact on life sciences can be game changing. We are pleased to collaborate with AbbVie, a global leader in the biopharmaceutical industry, to offer this unique opportunity to this competitively chosen startup."

The AbbVie Biotech Innovators Award was launched in 2024 in collaboration with SpinUp, a purpose-built laboratory for chemistry and biological work or wet lab incubator at the University of Toronto . The Award is to support early-stage Canadian biotechnology startup companies with the potential to generate transformational therapies in areas that align with AbbVie's therapeutic areas of focus: immunology, oncology, neuroscience, and eye care. Neuropeutics Inc will receive a year of laboratory space at no cost, in addition to access to SpinUp's core equipment, services, entrepreneurship programming, and research talent community at the University of Toronto . Neuropeutics Inc will also benefit from mentorship by AbbVie's scientific and business executives.

For more information on the AbbVie Biotech Innovators Award, please visit: https://spinup.utm.utoronto.ca/biotech-innovators-award/ .

About AbbVie
AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas – immunology, oncology, neuroscience, and eye care – and products and services in our Allergan Aesthetics portfolio.

For more information about AbbVie, please visit us at www.abbvie.ca . Follow AbbVie Canada on Instagram or find us on LinkedIn .

About SpinUp
SpinUp is the first wet lab startup incubator at the University of Toronto , Canada's leading centre for learning and discovery and one of the world's top-two universities for health science productivity . SpinUp is purpose built to drive life science innovation. It offers early-stage start-ups access to outstanding and highly subsidized wet lab space, equipment, entrepreneurship programming and expertise at a brand new, state-of-the-art research facility at U of T's Mississauga campus. Visit our website at spinup.utm.utoronto.ca and connect with us on Instagram and LinkedIn .

SpinUp is proudly part of U of T Entrepreneurship , a network of 12 accelerators across three campuses. Over the past 10 years, this network has supported more than 1,200 capital-backed companies, which have created 17,000 jobs and raised $12 billion in external investment. U of T now launches more research-based start-ups than any university in North America outside of MIT . The AbbVie Biotech Innovators Award is part of U of T Mississauga's Blue Ticket program at SpinUp, which provides a one-year SpinUp membership.

About Neuropeutics Inc  
Neuropeutics is a for-profit Canadian pharmaceutical company developing targeted therapies to extend neurodegenerative disease patients' survival and improve their quality of life. To learn more, please visit us at www.neuropeutics.ca , contact us at info@neuropeutics.ca , and connect with us on LinkedIn .

Neuropeutics Inc CSO & co-founder Dr. Janice Robertson (left) and Dr. Marc Shenouda, CEO & Co-Founder. (CNW Group/AbbVie Canada)

SOURCE AbbVie Canada

Cision View original content to download multimedia: http://www.newswire.ca/en/releases/archive/May2025/22/c0315.html

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

Adicet Bio to Participate in a Fireside Chat at the 2025 Jefferies Global Healthcare Conference

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference being held from June 3-5, 2025 in New York.

Details of the event are as follows:
Date: Wednesday, June 4, 2025
Time: 4:20 p.m. ET

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Zoono Group

Exclusive UK Packaging Agreement signed between Sharpak Aylesham Limited, Zoono, and OSY

Zoono Group Limited (Company) (ASX: ZNO) is pleased to update the market on an exclusive contract signed with Sharpak Aylesham Limited (Sharpak) and the Company’s partner in the food supply chain sector, OSY Group Limited (OSY).

Keep reading...Show less
Amplia Therapeutics

Accent Trial Data Demonstrates that Narmafotinib + Chemotherapy Combination Superior to Chemotherapy Alone

Amplia Therapeutics Limited (ASX: ATX), (“Amplia” or the “Company”), is pleased to announce important new data from our ongoing ACCENT clinical trial in pancreatic cancer. The trial is investigating the Company’s best-in-class FAK inhibitor narmafotinib in combination with standard-of-care chemotherapies gemcitabine and Abraxane. Fifteen (15) confirmed partial responses (PRs) have now been recorded in the trial, a level of response sufficient to demonstrate that the combination of narmafotinib and chemotherapy is superior to chemotherapy alone.
Keep reading...Show less
U.S. FDA Approves EMRELIS  for Adults With Previously Treated Advanced Non-Small Cell Lung Cancer  With High c-Met Protein Overexpression

U.S. FDA Approves EMRELIS for Adults With Previously Treated Advanced Non-Small Cell Lung Cancer With High c-Met Protein Overexpression

EMRELIS is the first and only treatment approved for previously treated advanced NSCLC patients with high c-Met protein overexpression who often face poor prognosis and have limited treatment options Lung cancer remains the leading cause of cancer-related deaths throughout the worl d 1

NORTH CHICAGO, Ill. , May 14, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that EMRELIS (telisotuzumab vedotin-tllv) has been granted accelerated approval by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with locally advanced or metastatic, non-squamous non-small cell lung cancer (NSCLC) with high c-Met protein overexpression (OE) who have received a prior systemic therapy. High c-Met protein overexpression is defined as ≥ 50% of tumor cells with strong (3+) staining as determined by an FDA-approved test. 2,3

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×